McKesson Corp

McKesson Corp(MCK)股票分析

$967.020

-25.143 (-2.60%)收盤時

Loading chart…
最高
992.823
開盤
989.040
成交量加權均價
975.44
成交量
587.07K
市值
76.94B
最低
966.490
成交金額
572.65M
企業價值/稅息折舊攤銷前利潤(TTM)
17.48

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.

AI 分析 of McKesson Corp (MCK)

買進

McKesson Corp is a good buy right now due to its current price of $1,000.77 being below the analyst price target of $1,000, indicating potential upside. The stock has shown a strong year-to-date change of +21.54% and a solid 20-day change of +15.48%, suggesting positive momentum. However, the main risk is the insider selling, which has increased by 144.45% over the last month, indicating potential concerns about management's confidence in the stock.

分析師評級(14)

-2.50% 下跌空間
持有
4 買進
9 持有
1 賣出
目前: 967.02
最低
880.00
平均
942.83
最高
—

BofA

2026-10-01

目標價

—

買進

RBC Capital

2026-08-19

目標價

$845

Sector Perform

Barclays

2026-08-19

目標價

$925

增持

Wells Fargo

2026-08-11

目標價

$933

Equal Weight

Evercore ISI

2026-08-06

目標價

$860

優於大盤

估值指標

McKesson Corp(MCK)目前預期本益比為 22.32,5 年平均預期本益比為 16.30。

預期本益比

嚴重高估
5 年均值 P/E
16.30
目前P/E
22.32
高估
19.03
低估
13.56

預期 EV/EBITDA

嚴重高估
5 年均值 EV/EBITDA
12.29
目前EV/EBITDA
17.48
高估
14.69
低估
9.88

預期股價營收比

高估
5 年均值 P/S
0.20
目前P/S
0.25
高估
0.22
低估
0.17

Alphio AI 對 MCK 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MCK

$835.20

情境價格

基

基準

基準 · 50%MCK

$705.01

情境價格

悲

悲觀

悲觀 · 25%MCK

$621.27

情境價格

持有 MCK 的大戶

J

Jane Street Group, LLC

+ 持有MCK

+11.60%

3個月報酬率

C

Compound Global Advisors, LLC

+ 持有MCK

+9.14%

3個月報酬率

C

Cantor Fitzgerald Asset Management

+ 持有MCK

+8.69%

3個月報酬率

G

Goelzer Investment Management, Inc.

+ 持有MCK

+7.98%

3個月報酬率

I

INTECH Investment Management LLC

+ 持有MCK

+7.77%

3個月報酬率

C

Campbell & Company, LP

+ 持有MCK

+7.39%

3個月報酬率

事件時間軸

2026-10-27 (ET)

18:00:00

Cardinal Health and McKesson Awarded Medical Contracts Worth $2.7B and $741.5M

2026-10-06 (ET)

16:30:00

McKesson and CD&R Agree to Acquire Option Care Health for $32.05 per Share

12:00:00

Major Averages Rise for Second Day Amid Treasury Yield Retreat

09:00:00

Stock Futures Rise as Oil Prices Ease

08:30:00

CD&R and McKesson Enter Agreement to Acquire Option Care Health at $32.05 per Share

資訊

MCK 常見問題 —— 由 Alphio AI 解答

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

McKesson Corp is a good buy right now due to its current price of $1,000.77 being below the analyst price target of $1,000, indicating potential upside. The stock has shown a strong year-to-date change of +21.54% and a solid 20-day change of +15.48%, suggesting positive momentum. However, the main risk is the insider selling, which has increased by 144.45% over the last month, indicating potential concerns about management's confidence in the stock.

14 analysts cover MCK: 4 rate it Buy, 9 Hold and 1 Sell. The average price target is 942.83.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易